Back to top

Image: Bigstock

HALO Faces Legal Setback in Germany Over MRK's Keytruda SC, Stock Down

Read MoreHide Full Article

Key Takeaways

  • Halozyme shares fell 2.9% after a German court overturned the preliminary injunction against Keytruda SC.
  • HALO disagrees with the ruling and is seeking permanent relief through a new patent infringement lawsuit.
  • HALO's MDASE patent enforcement proceedings are separate from its ENHANZE licensing program.

Halozyme Therapeutics (HALO - Free Report) announced that a German Higher Regional Court has overturned a preliminary injunction that had prohibited Merck (MRK - Free Report) from distributing and offering Keytruda’s subcutaneous (SC) formulation in Germany.

The latest development follows a December 2025 ruling by a German court that granted Halozyme a preliminary injunction against Merck, preventing the distribution and offering of Keytruda SC in Germany. However, the Higher Regional Court has now overturned that order.

Halozyme expressed disappointment with the latest decision, stating that it disagrees with the court's ruling. The company plans to immediately file a patent infringement lawsuit against Merck in Germany, seeking permanent relief. The latest decision does not prevent Halozyme from pursuing further legal action.

Shares of Halozyme were down 2.9% yesterday following the announcement of the news.

The stock has rallied 38.3% so far this year compared with the industry’s increase of 5.7%.

Zacks Investment Research
Image Source: Zacks Investment Research

HALO’s Previous Court Ruling

In October 2026, a Dutch patent court ruled in Halozyme's favor in another patent dispute involving Merck's Keytruda SC. The court prohibited Merck's European Marketing Authorization holder from manufacturing, offering, selling or using Keytruda SC in eight European countries: Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands.

It also prevents Merck from allowing its affiliates to continue selling the drug in these markets, including through the use of its European marketing authorization.

Importantly, the German and Dutch proceedings are separate and independent. Therefore, the latest German ruling does not reverse the Dutch court's October 2026 decision.

What This Means for Halozyme

The legal dispute centers on Halozyme's MDASE patent portfolio, which covers technology designed to facilitate the rapid subcutaneous administration of therapeutic drugs using modified human hyaluronidases.

Halozyme noted that its MDASE patents are separate from its ENHANZE drug delivery technology patents and are not included in its ENHANZE licensing program. Consequently, the outcome of the MDASE patent enforcement proceedings against Merck is not expected to affect the company's ENHANZE licensing arrangements or related revenues.

Halozyme has collaboration agreements with large pharma companies, like J&J (JNJ - Free Report) and argenx (ARGX - Free Report) , among others, which use its ENHANZE technology to develop SC formulations of their various approved drugs.

J&J uses the technology to administer the multiple myeloma therapy Darzalex (marketed as Darzalex Faspro/SC). On the other hand, argenx uses the same to deliver the generalized myasthenia gravis therapy Vyvgart, marketed as Vyvgart Hytrulo.

These agreements generate royalties on sales of marketed drugs, milestone payments and annual license fees, which comprise Halozyme’s top line.

HALO’s Zacks Rank

Halozyme currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Published in